The 36-month beta value for ALDX is also noteworthy at 1.47. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ALDX is 56.55M, and at present, short sellers hold a 3.23% of that float. The average trading volume of ALDX on April 09, 2024 was 569.75K shares.
ALDX) stock’s latest price update
Aldeyra Therapeutics Inc (NASDAQ: ALDX)’s stock price has gone decline by -7.20 in comparison to its previous close of 4.72, however, the company has experienced a 33.94% increase in its stock price over the last five trading days. 24/7 Wall Street reported 2024-04-07 that Although the number and size of insider purchases have been somewhat lower as the second quarter begins, the following beneficial owners and other insiders were still showing their love for these five stocks.
ALDX’s Market Performance
ALDX’s stock has risen by 33.94% in the past week, with a monthly rise of 13.77% and a quarterly rise of 35.60%. The volatility ratio for the week is 12.88% while the volatility levels for the last 30 days are 8.29% for Aldeyra Therapeutics Inc The simple moving average for the past 20 days is 34.31% for ALDX’s stock, with a -7.25% simple moving average for the past 200 days.
Analysts’ Opinion of ALDX
Many brokerage firms have already submitted their reports for ALDX stocks, with Oppenheimer repeating the rating for ALDX by listing it as a “Outperform.” The predicted price for ALDX in the upcoming period, according to Oppenheimer is $10 based on the research report published on April 03, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ALDX reach a price target of $10. The rating they have provided for ALDX stocks is “Buy” according to the report published on April 02nd, 2024.
H.C. Wainwright gave a rating of “Buy” to ALDX, setting the target price at $15 in the report published on April 27th of the previous year.
ALDX Trading at 29.31% from the 50-Day Moving Average
After a stumble in the market that brought ALDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.41% of loss for the given period.
Volatility was left at 8.29%, however, over the last 30 days, the volatility rate increased by 12.88%, as shares surge +20.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +44.08% upper at present.
During the last 5 trading sessions, ALDX rose by +33.94%, which changed the moving average for the period of 200-days by -43.26% in comparison to the 20-day moving average, which settled at $3.30. In addition, Aldeyra Therapeutics Inc saw 24.79% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALDX starting from PERCEPTIVE ADVISORS LLC, who purchase 37,712 shares at the price of $4.74 back on Apr 05 ’24. After this action, PERCEPTIVE ADVISORS LLC now owns 9,275,851 shares of Aldeyra Therapeutics Inc, valued at $178,755 using the latest closing price.
PERCEPTIVE ADVISORS LLC, the 10% Owner of Aldeyra Therapeutics Inc, purchase 140,281 shares at $4.67 during a trade that took place back on Apr 04 ’24, which means that PERCEPTIVE ADVISORS LLC is holding 9,238,139 shares at $655,112 based on the most recent closing price.
Stock Fundamentals for ALDX
Current profitability levels for the company are sitting at:
- -109.0 for the present operating margin
- 0.33 for the gross margin
The net margin for Aldeyra Therapeutics Inc stands at -93.85. The total capital return value is set at -0.34. Equity return is now at value -27.73, with -22.78 for asset returns.
Based on Aldeyra Therapeutics Inc (ALDX), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -1.94. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is -20.66.
Currently, EBITDA for the company is -42.53 million with net debt to EBITDA at 3.42. When we switch over and look at the enterprise to sales, we see a ratio of 333.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.44.
Conclusion
In summary, Aldeyra Therapeutics Inc (ALDX) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
